Scinovex
review Open AccessTop 1% cited

Diagnosis and Management of the Metabolic Syndrome

Circulation · 2005 · Vol. 112(17) · pp. 2735–2752
Scott M. GrundyJames I. CleemanStephen R. DanielsKaren A. DonatoRobert H. EckelBarry A. FranklinDavid J. GordonRonald M. KraussPeter J. SavageSidney C. SmithJohn A. SpertusFernando Costa

Abstract

The metabolic syndrome has received increased attention in the past few years. This statement from the American Heart Association (AHA) and the National Heart, Lung, and Blood Institute (NHLBI) is intended to provide up-to-date guidance for professionals on the diagnosis and management of the metabolic syndrome in adults. The metabolic syndrome is a constellation of interrelated risk factors of metabolic origin— metabolic risk factors —that appear to directly promote the development of atherosclerotic cardiovascular disease (ASCVD).1 Patients with the metabolic syndrome also are at increased risk for developing type 2 diabetes mellitus. Another set of conditions, the underlying risk factors , give rise to the metabolic risk factors. In the past few years, several expert groups have attempted to set forth simple diagnostic criteria to be used in clinical practice to identify patients who manifest the multiple components of the metabolic syndrome. These criteria have varied somewhat in specific elements, but in general they include a combination of both underlying and metabolic risk factors. The most widely recognized of the metabolic risk factors are atherogenic dyslipidemia, elevated blood pressure, and elevated plasma glucose. Individuals with these characteristics commonly manifest a prothrombotic state and a pro-inflammatory state as well. Atherogenic dyslipidemia consists of an aggregation of lipoprotein abnormalities including elevated serum triglyceride and apolipoprotein B (apoB), increased small LDL particles, and a reduced level of HDL cholesterol (HDL-C). The metabolic syndrome is often referred to as if it were a discrete entity with a single cause. Available data suggest that it truly is a syndrome, ie, a grouping of ASCVD risk factors, but one that probably has more than one cause. Regardless of cause, the syndrome identifies individuals at an elevated risk for ASCVD. The magnitude of the increased risk can vary according to which components of the syndrome are …

Diabetes, Cardiovascular Risks, and LipoproteinsLipid metabolism and disordersLipoproteins and Cardiovascular HealthMetabolic syndromeMedicineDyslipidemiaDiabetes mellitusInternal medicineRisk factorApolipoprotein BType 2 Diabetes MellitusDiseaseEndocrinology

MeSH terms

Diabetes Mellitus, Type 2HumansLipoproteinsNational Institutes of Health (U.S.)Risk FactorsSocieties, MedicalUnited StatesMetabolic Syndrome
Citations
11,687
FWCI
217.61
field-weighted impact
References
196
Percentile
100%
vs. same field & year
Citations per year
Cited by
Anti-diabetes role of ginger
Journal of Medicinal Plants Studies · 2022 · 0 citations
Heart Disease and Stroke Statistics—2010 Update
Circulation · 2009 · 5,595 citations
Heart Disease and Stroke Statistics—2009 Update
Circulation · 2009 · 3,916 citations
Obstructive Sleep Apnea
Hypertension · 2011 · 648 citations
Pathophysiology of Human Visceral Obesity: An Update
Physiological Reviews · 2013 · 2,670 citations
References
The metabolic syndrome
The Lancet · 2010 · 6,311 citations
The Metabolic Syndrome
Archives of Internal Medicine · 2003 · 2,063 citations
Obesity is associated with macrophage accumulation in adipose tissue
Journal of Clinical Investigation · 2003 · 8,580 citations
Metabolic origins and clinical significance of LDL heterogeneity
Journal of Lipid Research · 2002 · 890 citations
Prevalence and outcomes of anemia in cancer: a systematic review of the literature
The American Journal of Medicine · 2004 · 870 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.